Scientists Crack Ketamine's Code for New Depression Drugs

For the first time, scientists have figured out precisely how ketamine lifts depression so quickly, opening the door to treatments that work just as fast without the serious side effects.

Researchers at Weill Cornell Medicine reverse engineered ketamine's effects in the brain, identifying the exact receptors and pathways that make it work. Their findings could transform treatment for the 30 percent of depression patients who don't respond to standard medications.

The problem with current options is real. One third of people with depression must cycle through multiple medications before finding relief. Another third have treatment resistant depression that doesn't respond to anything. Ketamine can help these patients feel better within hours, but the relief fades quickly and the drug carries risks including changes in heart rate, feelings of disconnection, and addiction potential.

Dr. Conor Liston and Dr. Joshua Levitz discovered that ketamine targets specific opioid receptors on specialized brain cells called interneurons in the prefrontal cortex. When people experience chronic stress, these interneurons become hyperactive and suppress overall brain activity, contributing to depression. Ketamine reverses this effect by calming the interneurons down for just 15 to 20 minutes, which appears to be enough to jumpstart recovery.

The team then did something remarkable. They recreated ketamine's antidepressant effects in mice using small doses of three existing drugs that target the same pathway. Because the doses are so low, the combination produces the same benefits without the troubling side effects.

In a second study, the researchers uncovered how ketamine's benefits last beyond that initial 20 minute window. They found that two receptors in brain cells, TrkB and mGluR5, must communicate with each other to maintain the antidepressant effects. This interaction strengthens connections between brain cells that have weakened during depression while preventing those connections from weakening again.

The Bright Side

The researchers are already preparing to launch a clinical trial testing their three drug combination in people. Because all three medications have already been proven safe and effective in humans for other uses, the path to helping patients could be faster than developing an entirely new drug from scratch.

This breakthrough matters beyond depression treatment. Understanding exactly how brain circuits recover could unlock new approaches for other mental health conditions that involve similar brain regions and pathways.

Millions of people struggling with depression that doesn't respond to current treatments may soon have access to relief that works quickly, safely, and lasts.